Jennifer Cochran and Carolyn Bertozzi have collaborated to develop a bifunctional molecule called a polyspecific integrin-binding peptide (PIP)-LYTAC that can bind to integrins expressed on the surface of cancer cells and trigger their degradation via the lysosome.
Researchers at Stanford have developed synthetic derivatives of a natural product, azapodophyllotoxin (AZP), that exhibit remarkable anticancer activities.
Histone acetyltransferase 1 (HAT1) is an enzyme which acetylates lysine on histone proteins and is intricately involved with regulating gene transcription.
Stanford researches have formulated a robust database called PRECOG (Prediction of Clinical Outcomes from Genomics) that connects cancer genome expression and patient survival/outcomes in a more predictive and extensive collection than any other signature on the market.
Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.
Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases.
Researchers at Stanford have developed humanized therapeutic antibodies to treat cancers, particularly melanoma, inflammatory disorders such as sarcoidosis and skin and organ fibrosis.
Disease indication - Cancer, specifically:
-highly mutated cancers, including the ~20% of cancer with BAF complex mutations
-combination therapy with ATR inhibitors
Researchers at Stanford have developed agents to enhance the therapeutic efficacy of a variety of anti-cancer therapeutics. Cell loss by apoptosis occurs in normal development and in tumor environments.
Researchers in Dr. Mark Kay's lab have developed a patented approach to inducing apoptosis that could represent a new strategy against cancer and other diseases.